FindTrial
Sign In

Study for the effect of iodine supplementation during antithyroid drug therapy for Graves' disease

Study for the effect of iodine supplementation during antithyroid drug therapy for Graves' disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900028109
Enrollment
Unknown
Registered
2019-12-12
Start date
2020-06-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves’ disease

Interventions

Group 1:Iodine supplemented
Group 2:Iodine restricted

Sponsors

The Second Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 16-65 years old; 2. patients newly diagnosed with GD; 3. thyroid enlargement of Grade 1 or 2; 4. the patient has not been treated with any antithyroid drugs.

Exclusion criteria

Exclusion criteria: 1. nodular goitre associated with hyperthyroidism or hyperthyroidism for any reasons other than GD; 2. moderate or severe thyroid-associated eye diseases; 3. thyroid enlargement of Grade 3 or above; 4. hyperthyroid heart disease or atrial fibrillation; 5. recurrent GD; 6. pregnant and lactating women; 7. abnormal liver function, with transaminase level 3 times higher than the upper normal limit; 8. hyperthyroid crisis.

Design outcomes

Primary

MeasureTime frame
Goiter scale;FT3;FT4;TSH;TRAb;—

Contacts

Public ContactHuibin Huang

The Second Affiliated Hospital of Fujian Medical University

huibinhuang@aliyun.com+86 13313872001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026